Climb Bio Inc (CLYM)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$10.91

+0.62 (+6.03%)

Market Cap: $591.02M

Last updated: Oct 16, 2026 at 1:54 PM ET

Earnings

Performance (10Y)

Beat Rate

56%(10/18)

Avg Surprise

+9.31%

Streak

2 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.19

Range$-0.23 - $-0.16

10 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.21+8.2%

60d ago$-0.21+6.0%

30d ago$-0.19+0.2%

7d ago$-0.190.0%

Current$-0.19

Revenue Consensus

Range$0 - $0

15 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.06

Range$-0.14 - $0.01

10 analysts

Revenue Consensus

Range$0 - $0

15 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.06	$-0.14 - $0.01	-	-	10	-	-
Sep 30, 2026Sep 26EST	-	$-0.19	$-0.23 - $-0.16	-	-	10	4 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-0.18	$-0.22	$-0.27 - $-0.18	+18.18%	Beat	8	5 0 30d	-38.5%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-0.20	$-0.30	$-0.57 - $-0.25	+33.33%	Beat	8	0 2 30d	+35.5%
Dec 31, 2025Dec 25 Reported Mar 5, 2026Reported Mar 5	$-0.26	$-0.19	$-0.21 - $-0.17	-38.89%	Miss	3	No revisions (30d)	-750.0%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$-0.19	$-0.15	$-0.15 - $-0.14	-26.67%	Miss	2	No revisions (30d)	-46.2%
Jun 30, 2025Jun 25 Reported Aug 12, 2025Reported Aug 12	$-0.13	$-0.18	$-0.18 - $-0.18	+27.78%	Beat	0	No revisions (30d)	+92.8%
Mar 31, 2025Mar 25 Reported May 14, 2025Reported May 14	$-0.31	$-0.15	-	-106.67%	Miss	-	-	-404.9%
Dec 31, 2024Dec 24 Reported Mar 25, 2025Reported Mar 25	$0.04	N/A	-	+126.67%	Beat	-	-	+130.4%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-0.13	N/A	-	N/A	Beat	-	-	+11.3%
Jun 30, 2024Jun 24 Reported Aug 14, 2024Reported Aug 14	$-1.81	N/A	-	N/A	Beat	-	-	-830.6%
Mar 31, 2024Mar 24 Reported May 15, 2024Reported May 15	$-0.06	N/A	-	N/A	Beat	-	-	+92.7%
Dec 31, 2023Dec 23 Reported Mar 4, 2024Reported Mar 4	$-0.13	$-0.13	-	-1.08%	Miss	-	-	+54.7%
Sep 30, 2023Sep 23 Reported Nov 6, 2023Reported Nov 6	$-0.15	$-0.14	-	-4.71%	Miss	-	-	+60.4%
Jun 30, 2023Jun 23 Reported Sep 11, 2023Reported Sep 11	$-0.19	$-0.16	-	-21.56%	Miss	-	-	+65.3%
Mar 31, 2023Mar 23 Reported May 11, 2023Reported May 11	$-0.84	$-0.25	-	-236.00%	Miss	-	-	-68.0%
Dec 31, 2022Dec 22 Reported Mar 31, 2023Reported Mar 31	$-0.29	$-0.33	-	+12.12%	Beat	-	-	-123.2%
Sep 30, 2022Sep 22 Reported Nov 14, 2022Reported Nov 14	$-0.37	$-0.43	-	+13.95%	Beat	-	-	+47.1%
Jun 30, 2022Jun 22 Reported Aug 15, 2022Reported Aug 15	$-0.56	$-0.47	-	-19.15%	Miss	-	-	+8.2%
Mar 31, 2022Mar 22 Reported May 16, 2022Reported May 16	$-0.50	$-0.50	-	+0.00%	Beat	-	-	-
Dec 31, 2021Dec 21 Reported Mar 31, 2022Reported Mar 31	$1.25	$-0.63	-	+298.41%	Beat	-	-	-
Sep 30, 2021Sep 21 Reported Nov 8, 2021Reported Nov 8	$-0.70	$-0.85	-	+17.65%	Beat	-	-	-
Jun 30, 2021Jun 21 Reported Jul 16, 2021Reported Jul 16	$-0.61	N/A	-	+74.26%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-13.14	EV/EBITDA	N/A
Price/FCF	-15.66x	FCF Yield	-6.39%
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-27.10%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	31.45x	Quick Ratio	31.45x
Trading Statistics
Beta	-0.03	Avg Volume	1.35M
52-Week High	$18.33	52-Week Low	$1.64

Technical Indicators Dashboard

Moving Averages

SMA 10$10.76

SMA 20$11.57

SMA 50$13.78

SMA 200$10.05

EMA 10$10.90

EMA 20$11.59

EMA 50$12.63

EMA 200$10.32

MACD

Line: -0.91Signal: -0.93Hist: 0.02

ADX

ADX: 41.8+DI: 11.2-DI: 27.0

Aroon & PSAR

Aroon Up4.0

Aroon Down96.0

PSAR$10.09

Bollinger Bands

Upper Band$13.90

Lower Band$9.23

%B Position4041%(Upper)

Band Width0.36

RSI (14-Day)

Neutral

38.1

Momentum Oscillators

Stoch %K20.4

Stoch %D14.3

Williams %R-55.4

ROC (10d)-1.4%

Momentum-0.16

CCI (20d)-66.8

MFI (14d)26.9

Volatility Measures

ATR (14d)$0.77(7.0%)

StdDev (20d)1.17

Hist Vol59.2%(High)

Volume Flow

VWAP$10.71

OBV59.9M

AD Line2.8M

CMF (20d)-0.248

Volume Metrics

Avg Vol (20d)1.3M

Vol Ratio0.4x(Low)

VWMA (20d)$11.94

Pivot Points

R3$11.14

R2$10.89

R1$10.59

Pivot Point$10.34

S1$10.04

S2$9.79

S3$9.49

Advanced Oscillators

TSI-33.69

Ultimate Osc49.5

KST-259.86

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Cost of Revenue	$0	$0	$30,000	$0	$0	$0	N/A	$0	$0	$0	N/A	$0
Gross Profit	$0	$0	$-30,000	$0	$0	$0	N/A	$0	$0	$0	N/A	$0

Operating Expenses	$15.36M	$15.21M	$19.30M	$14.89M	$10.68M	$23.02M	$10.91M	$11.73M	$56.37M	$3.00M	$5.12M	$5.00M
R&D	$9.71M	$9.37M	$13.74M	$9.07M	$6.58M	$17.33M	$5.96M	$6.24M	$52.70M	$1.09M	$3.13M	$2.88M
SG&A	$5.64M	$5.84M	$5.56M	$5.82M	$4.10M	$5.69M	$4.95M	$5.49M	$3.67M	$1.91M	$2.00M	$2.13M
Operating Income	$-15,359,000	$-15,211,000	$-19,296,000	$-14,892,000	$-10,677,000	$-23,018,000	$-10,911,000	$-11,732,000	$-56,372,000	$-3,005,000	$-5,122,000	$-5,001,000

Interest Income	$1.85M	$1.51M	$0	$2.04M	$2.17M	$2.29M	$0	$2.79M	$1.49M	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-13,498,000	$-13,722,000	$-17,516,000	$-12,888,000	$-8,666,000	$-20,781,000	$-8,416,000	$-8,895,000	$-54,889,000	$-1,697,000	$-3,641,000	$-3,968,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-13,498,000	$-13,722,000	$-17,516,000	$-12,888,000	$-8,666,000	$-20,781,000	$-8,416,000	$-8,895,000	$-54,889,000	$-1,697,000	$-3,641,000	$-3,968,000

EBITDA	$-15,706,000	$-15,503,000	$-19,777,000	$-15,419,000	$-11,372,000	$-23,737,000	$-11,436,000	$-11,849,000	$-56,374,000	$-3,068,000	$-5,468,000	$-5,754,000
EBIT	$-15,353,000	$-15,236,000	$-19,296,000	$-14,925,000	$-10,839,000	$-23,068,000	$-10,911,000	$-11,680,000	$-56,374,000	$-3,005,000	$-5,122,000	$-5,001,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about CLYM

News

Climb Bio (NasdaqGM:CLYM) Stock Forecast & Analyst Predictions

Climb Bio (NasdaqGM:CLYM) is forecast to have its earnings decline by 27.2% per annum, while revenue is expected to grow by 83.8% annually. The company has seen significant price target increases from analysts recently...

Simply Wall Street•Oct 2, 2026 11:35 AM ET10/2/26•Neutral

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio, Inc. announced that its executive team will participate in two upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026...

markets.businessinsider.com•Sep 2, 2026 3:00 AM ET9/2/26•Somewhat-Bullish

ELYM: Eliem Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock information for Eliem Therapeutics Inc (ELYM), including its current stock price, market capitalization, trading volume, and key financial metrics. It also features trending news...

Stocktwits•Jul 26, 2026 3:39 PM ET7/26/26•Neutral

CLYM Valuation and Fair Value

P/E: -13.1x
P/FCF: -15.7x
P/B: 3.5x

See GNG's fair value

CLYM Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -27.1%
FCF yield: -6.4%

CLYM Competitors

Company	Ticker
Nuvectis Pharma Inc	NVCT
Solid Biosciences LLC	SLDB
Weave Communications Inc	WEAV
Fulgent Genetics Inc	FLGT
Ironwood Pharmaceuticals Inc	IRWD
CorMedix Inc	CRMD
Olema Pharmaceuticals Inc	OLMA
Orthopediatrics Corp	KIDS

Sector: Healthcare

CLYM Analyst Ratings

Consensus: Buy
Analysts: 15
Strong Buy: 2
Buy: 13
Hold: 0
Sell: 0
Strong Sell: 0

CLYM Bull Case vs Bear Case

Bull case

100.0% of CLYM's analyst ratings are Buy or Strong Buy.

CLYM Earnings: Beat Rate and Next Report

Beat rate: 4 of 8 quarters (50.0%)
Average surprise: 4.1%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.19
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 4 up, 1 down

Frequently Asked Questions About CLYM

Does CLYM pay dividends?

Climb Bio Inc (CLYM) does not currently pay a regular dividend.

What is CLYM's market cap?

Climb Bio Inc (CLYM) has a market capitalization of $591.02M with a current stock price of $10.91.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In